Clinical impact of two different intraoperative parathyroid hormone assays in primary and renal hyperparathyroidism

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism, published as a clinical trial.

Intraoperative parathyroid hormone (PTH) monitoring predicts successful surgery for primary hyperparathyroidism (pHPT).

In renal HPT, intraoperative PTH assays can define whether parathyroid resection is adequate.

Who Took Part

According to the abstract, 91 patients were involved.

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Intraoperative PTH was measured with two different immunometric assays (Immulite Turbo DPC and ADVIA Centaur assay) in 91 patients undergoing parathyroidectomy for primary (n=57) and renal (n=34) hyperparathyroidism.

How the Study Was Run

PTH was monitored preoperatively, 10, 20, and 30 min after parathyroidectomy and 24 h postoperatively.

What Was Measured

Intraoperative parathyroid hormone (PTH) monitoring predicts successful surgery for primary hyperparathyroidism (pHPT).

PubMed files the paper under topics including Chemistry, Clinical, Hyperparathyroidism, Primary, Hyperparathyroidism, Secondary, Immunoassay, Intraoperative Care, Kidney Diseases and Parathyroid Hormone.

What This Means in Plain Language

This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 91 patients in people with hyperparathyroidism.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (European journal of endocrinology), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.